You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 27, 2024

Claims for Patent: 8,536,200

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,536,200

Title:	Pyridinone compounds
Abstract:	The invention is directed to pyridinone compounds useful for modulating Met kinase, having the following structure: ##STR00001## and is further directed to pharmaceutical compositions comprising the compound; and methods for treating proliferative diseases, such as cancer by the administration of this compound.
Inventor(s):	Borzilleri; Robert M. (New Hope, PA), Schroeder; Gretchen M. (Ewing, NJ), Cai; Zhen-Wei (Belle Mead, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	12/941,419
Patent Claims:	1. A method of treating cancer in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of Compound of Formula I: ##STR00014## or a salt thereof. 2. The method of claim 1 wherein said cancer is selected from bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreas/gall bladder cancer, prostate cancer, thyroid cancer, osteosarcoma, rhabdomyosarcoma, MFH/fibrosarcoma, glioblastomas/astrocytomas, melanoma, and mesothelioma. 3. The method of claim 2 wherein said cancer is selected from bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreas/gall bladder cancer, prostate cancer, and thyroid cancer. 4. The method according to claim 2 wherein said patient is a human. 5. The method according to claim 1, further comprising administering an additional anticancer agent. 6. The method according to claim 5 wherein said other anticancer agent is selected from gefitinib, erlotinib, and cetuximab. 7. The method according to claim 1, further comprising administering radiation therapy. 8. The method according to claim 1, wherein said cancer is dependent upon Met activation, wherein the Met activation is regulated by gene amplification, an activated Met mutation and/or HGF stimulation.

Details for Patent 8,536,200

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2026-11-08
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2026-11-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.